Human single chain antibodies against heparin: Selection, characterization, and effect on coagulation

Blood

Volumn 99, Issue 7, 2002, Pages 2427-2433

  Van De Westerlo, Els M A ^b   Smetsers, Toon F C M ^a,b   Dennissen, Michel A B A ^a,b   Linhardt, Robert J ^a,b   Veerkamp, Jacques H ^a,b   Van Muijen, Goos N P ^a,b   Van Kuppeveit, Toin H ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITHROMBIN III; CHONDROITIN SULFATE; EPITOPE; GLYCOSAMINOGLYCAN; GLYCOSIDASE; HEPARAN SULFATE; HEPARIN; HEPARIN ANTAGONIST; SULFATE;

ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTICOAGULATION; ANTIGEN ANTIBODY REACTION; ARTICLE; BASOPHIL; BLOOD CLOTTING; ENZYME ACTIVITY; HUMAN; MAST CELL; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHAGE DISPLAY; PRIORITY JOURNAL; RAT; SULFATION; TISSUE SECTION;

EID: 0036530050     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.7.2427     Document Type: Article

References (29)

1. Heparan sulfate: A piece of information
2. Proteoglycans: Structures and interactions
3. Mechanisms of angiogenesis
4. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
5. Vascular endothelial growth factor is a secreted angiogenic mitogen
6. Interaction of heparin with human angiogenin
7. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors
8. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate
9. Protein-glycosaminoglycan interactions: Infectiological aspects
10. Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility
11. Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors
12. Mechanism of the anticoagulant action of heparin
13. Developmental changes in heparan sulfate expression: In situ detection with mAbs
14. Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody
15. Heparan sulfate heterogeneity in skeletal muscle basal lamina: Demonstration by phage display-derived antibodies
16. Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: Further evidence for heparan sulfate heterogeneity in the kidney
17. Antibody fragments from a 'single pot' phage display library as immunochemical reagents
18. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
19. Regulation of heparin therapy
20. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
21. Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells
22. Glycosaminoglycans and the regulation of blood coagulation
23. Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin
24. Allergy to protamine sulfate
25. Heparin, heparinoids and heparin oligosachharides: Structure and biological activities
26. Heparinoids: Structure, biological activities and therapeutic applications
27. Therapeutic uses of heparin beyond its traditional role as an anticoagulant
28. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops